JP2014503209A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503209A5 JP2014503209A5 JP2013544971A JP2013544971A JP2014503209A5 JP 2014503209 A5 JP2014503209 A5 JP 2014503209A5 JP 2013544971 A JP2013544971 A JP 2013544971A JP 2013544971 A JP2013544971 A JP 2013544971A JP 2014503209 A5 JP2014503209 A5 JP 2014503209A5
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- antibody
- fusion protein
- construct
- igg4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims 37
- 102000018358 immunoglobulin Human genes 0.000 claims 37
- 108020001507 fusion proteins Proteins 0.000 claims 17
- 102000037865 fusion proteins Human genes 0.000 claims 17
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 4
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002327 eosinophilic effect Effects 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000028185 Angioedema Diseases 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 208000006968 Helminthiasis Diseases 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 241000243981 Onchocerca Species 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 208000023819 chronic asthma Diseases 0.000 claims 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000002497 edematous effect Effects 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 206010057271 eosinophilic colitis Diseases 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 201000001561 eosinophilic gastritis Diseases 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 208000024711 extrinsic asthma Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 208000037916 non-allergic rhinitis Diseases 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000015768 polyposis Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061425858P | 2010-12-22 | 2010-12-22 | |
| US61/425,858 | 2010-12-22 | ||
| PCT/AU2011/001662 WO2012083370A1 (en) | 2010-12-22 | 2011-12-22 | Modified antibody with improved half-life |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016255652A Division JP6334669B2 (ja) | 2010-12-22 | 2016-12-28 | 改善された半減期を有する修飾された抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503209A JP2014503209A (ja) | 2014-02-13 |
| JP2014503209A5 true JP2014503209A5 (enExample) | 2015-02-19 |
| JP6147670B2 JP6147670B2 (ja) | 2017-06-14 |
Family
ID=46312907
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013544971A Active JP6147670B2 (ja) | 2010-12-22 | 2011-12-22 | 改善された半減期を有する修飾された抗体 |
| JP2016255652A Active JP6334669B2 (ja) | 2010-12-22 | 2016-12-28 | 改善された半減期を有する修飾された抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016255652A Active JP6334669B2 (ja) | 2010-12-22 | 2016-12-28 | 改善された半減期を有する修飾された抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9505826B2 (enExample) |
| EP (1) | EP2654790B1 (enExample) |
| JP (2) | JP6147670B2 (enExample) |
| KR (1) | KR101941514B1 (enExample) |
| CN (1) | CN103429261A (enExample) |
| AU (1) | AU2011349049B2 (enExample) |
| BR (1) | BR112013016235B1 (enExample) |
| CA (1) | CA2824279A1 (enExample) |
| EA (1) | EA201390923A1 (enExample) |
| ES (1) | ES2720136T3 (enExample) |
| IL (1) | IL227081B (enExample) |
| MX (1) | MX2013007392A (enExample) |
| PT (1) | PT2654790T (enExample) |
| WO (1) | WO2012083370A1 (enExample) |
| ZA (1) | ZA201305123B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103429261A (zh) * | 2010-12-22 | 2013-12-04 | 塞法隆澳大利亚股份有限公司 | 半寿期改进的修饰抗体 |
| CN104203982B (zh) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| EP2912065A4 (en) | 2012-10-25 | 2016-10-19 | True North Therapeutics Inc | ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF |
| RS63212B1 (sr) | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | Antikomplementna c1s antitela i njihove primene |
| JP6335189B2 (ja) | 2012-12-17 | 2018-05-30 | トリリアム・セラピューティクス・インコーポレイテッドＴｒｉｌｌｉｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ＳＩＲＰアルファ−Ｆｃ融合体でのＣＤ４７＋疾患細胞の治療 |
| ITTO20130012A1 (it) * | 2013-01-09 | 2014-07-10 | Metheresis Translational Res S A | Nuovi frammenti anticorpali, relative composizioni ed usi |
| JP2016528167A (ja) | 2013-04-29 | 2016-09-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ヒトＦｃＲｎ結合改変抗体及び使用方法 |
| ES2774976T3 (es) | 2013-04-29 | 2020-07-23 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado |
| KR102266819B1 (ko) | 2013-04-29 | 2021-06-18 | 에프. 호프만-라 로슈 아게 | Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법 |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| KR101895634B1 (ko) | 2013-05-31 | 2018-09-05 | 한미약품 주식회사 | 변이된 힌지 영역을 포함하는 IgG4 Fc 단편 |
| WO2015003149A2 (en) | 2013-07-05 | 2015-01-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Soluble cd33 for treating myelodysplastic syndromes (mds) |
| ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| RU2698969C2 (ru) | 2014-01-15 | 2019-09-02 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с улучшенной способностью связываться с белком а |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| SI3166970T1 (sl) | 2014-07-10 | 2021-09-30 | Bioarctic Ab | Izboljšana A-beta protofibril vezavna protitelesa |
| WO2016036918A1 (en) * | 2014-09-03 | 2016-03-10 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
| EA037749B1 (ru) | 2014-10-29 | 2021-05-18 | Тева Фармасьютикалз Острэйлиа Пти Лтд | ВАРИАНТЫ ИНТЕРФЕРОНА 2b |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| KR102654033B1 (ko) | 2014-12-08 | 2024-04-02 | 1글로브 바이오메디칼 씨오., 엘티디. | 가용성 유니버셜 adcc 증강 합성 융합 유전자 및 펩티드 기술 및 그 용도 |
| EP3303386B1 (en) | 2015-06-05 | 2024-08-28 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| CA2989116A1 (en) * | 2015-06-12 | 2016-12-15 | Ubi Pharma Inc | Immunoglobulin fusion proteins and uses thereof |
| US20160362473A1 (en) * | 2015-06-12 | 2016-12-15 | Ubi Pharma Inc | Immunoglobulin fusion proteins and uses thereof |
| US11820807B2 (en) * | 2015-06-12 | 2023-11-21 | Ubi Pharma Inc | Immunoglobulin fusion proteins and uses thereof |
| KR102644875B1 (ko) | 2015-07-23 | 2024-03-06 | 베링거잉겔하임인터내쇼날유한회사 | Il-23a 및 b-세포 활성화 인자(baff)를 표적화하는 화합물 및 이의 용도 |
| EP3222672A1 (de) * | 2016-03-23 | 2017-09-27 | LANXESS Deutschland GmbH | Metallazopigmente |
| CN108472371B (zh) * | 2016-07-05 | 2022-05-24 | 江苏恒瑞医药股份有限公司 | Egfr抗体-药物偶联物及其在医药上的应用 |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| KR102777127B1 (ko) | 2016-08-02 | 2025-03-07 | 비스테라, 인크. | 조작된 폴리펩티드 및 그의 용도 |
| PT3500299T (pt) | 2016-08-19 | 2024-02-21 | Beigene Switzerland Gmbh | Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro |
| EP3525583B8 (en) | 2016-10-12 | 2025-09-10 | Bioverativ USA Inc. | Anti-c1s antibodies and methods of use thereof |
| US11446315B2 (en) | 2016-11-03 | 2022-09-20 | Pf Argentum Ip Holdings Llc | Enhancement of CD47 blockade therapy by proteasome inhibitors |
| AU2017373889B2 (en) | 2016-12-07 | 2025-01-02 | Ac Immune Sa | Anti-Tau antibodies and methods of use |
| CN110248959B (zh) | 2016-12-07 | 2023-06-30 | 基因泰克公司 | 抗tau抗体和使用方法 |
| CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
| CN117018189A (zh) * | 2017-05-26 | 2023-11-10 | 葛兰素史密斯克莱知识产权发展有限公司 | 生物制药组合物和相关方法 |
| TW202515616A (zh) | 2017-06-26 | 2025-04-16 | 英屬開曼群島商百濟神州有限公司 | 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途 |
| KR102709785B1 (ko) | 2017-09-29 | 2024-09-24 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Ｉｌ－５ 항체, 이의 항원 결합 단편 및 이의 의학적 적용 |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| CN109942706A (zh) | 2017-12-21 | 2019-06-28 | 三生国健药业（上海）股份有限公司 | 结合人il-5的单克隆抗体、其制备方法和用途 |
| EP3892632A4 (en) | 2018-12-05 | 2022-08-17 | Bica Therapeutics Inc. | MODIFIED PRODUCT OF FC DOMAIN OF ANTIBODIES |
| CN110297093B (zh) * | 2019-03-18 | 2022-04-22 | 山西瑞豪生物科技有限公司 | 一种检测人免疫球蛋白g4的方法和试剂盒 |
| CN113507938B (zh) | 2019-03-29 | 2024-04-16 | 广东恒瑞医药有限公司 | 包含抗il-5抗体的药物组合物及其用途 |
| WO2021138407A2 (en) * | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| JP2023512456A (ja) | 2020-01-13 | 2023-03-27 | ネオイミューンテック， インコーポレイテッド | Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法 |
| CN112225807B (zh) * | 2020-10-30 | 2021-09-07 | 上海洛启生物医药技术有限公司 | 抗il5纳米抗体及其应用 |
| US20230405096A1 (en) * | 2020-11-18 | 2023-12-21 | Green Cross Corporation | Adamts13 variant having increased escaping rate or activity against autoantibody |
| CN117946281A (zh) * | 2020-11-19 | 2024-04-30 | 舒泰神（北京）生物制药股份有限公司 | 长效神经生长因子多肽及其用途 |
| TW202322850A (zh) * | 2021-08-05 | 2023-06-16 | 美商美國禮來大藥廠 | 抗體最佳化 |
| JP2025526384A (ja) | 2022-07-27 | 2025-08-13 | アブリンクス エン．ヴェー． | 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド |
| WO2024048683A1 (ja) | 2022-08-30 | 2024-03-07 | ミラバイオロジクス株式会社 | 人工タンパク質及び医薬組成物 |
| KR20240072322A (ko) * | 2022-11-10 | 2024-05-24 | (주)네오크레마 | Il-22를 포함하는 융합 단백질 및 이의 용도 |
| EP4658310A1 (en) | 2023-01-30 | 2025-12-10 | Kymab Limited | Antibodies |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| CN120189527A (zh) * | 2025-05-27 | 2025-06-24 | 南方医科大学第三附属医院（广东省骨科研究院） | 一种多肽与抗体Fc片段的偶联物、药物组合物及其用途 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| IT1237881B (it) | 1989-12-12 | 1993-06-18 | Fast Spa | Struttura a profilo complesso, applicabile su apparecchi agitatori, per il bloccaggio di barattoli di vernice, aventi coperchi comunque diversificati |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| AR248044A1 (es) | 1992-02-06 | 1995-05-31 | Schering Corp | Una secuencia de adn que codifica anticuerpos monoclonales humanizados contra interleuquinas humanas, metodo de obtencion y de seleccion de dichos anticuerpos, vector recombinante y celula huesped. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| GB9412230D0 (en) * | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| USRE39548E1 (en) | 1994-06-17 | 2007-04-03 | Celltech R&D Limited | Interleukin-5 specific recombinant antibodies |
| US6056957A (en) | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
| EP0800536B1 (en) | 1994-12-23 | 2006-11-29 | Smithkline Beecham Corporation | Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders |
| US5783184A (en) | 1994-12-23 | 1998-07-21 | Smithkline Beecham Corporation | Method for treatment and diagnosis of IL-5 mediated disorders |
| US5683892A (en) | 1994-12-23 | 1997-11-04 | Smithkline Beecham Corporation | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| CA2320403A1 (en) | 1998-02-25 | 1999-09-02 | Lexigen Pharmaceuticals Corporation | Enhancing the circulating half-life of antibody-based fusion proteins |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| PT1355919E (pt) * | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| MXPA04009418A (es) * | 2002-03-29 | 2005-06-08 | Schering Corp | Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos. |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| GB0612928D0 (en) * | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| WO2008134046A1 (en) * | 2007-04-27 | 2008-11-06 | Genentech, Inc. | Potent, stable and non-immunosuppressive anti-cd4 antibodies |
| US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| HUE028958T2 (en) * | 2008-02-08 | 2017-01-30 | Medimmune Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| CN102369021B (zh) | 2008-12-19 | 2016-09-07 | 宏观基因有限公司 | 共价双抗体及其用途 |
| AU2010206681A1 (en) * | 2009-01-23 | 2011-09-01 | Biogen Idec Ma Inc. | Stabilized Fc polypeptides with reduced effector function and methods of use |
| BRPI1007005A2 (pt) * | 2009-01-29 | 2016-03-22 | Medimmune Llc | anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6 |
| US8435523B2 (en) | 2009-05-04 | 2013-05-07 | Abbott Research B.V. | Antibodies against nerve growth factor (NGF) with enhanced in vivo stability |
| CN103429261A (zh) * | 2010-12-22 | 2013-12-04 | 塞法隆澳大利亚股份有限公司 | 半寿期改进的修饰抗体 |
-
2011
- 2011-12-22 CN CN201180068272XA patent/CN103429261A/zh active Pending
- 2011-12-22 ES ES11850362T patent/ES2720136T3/es active Active
- 2011-12-22 AU AU2011349049A patent/AU2011349049B2/en active Active
- 2011-12-22 CA CA2824279A patent/CA2824279A1/en not_active Abandoned
- 2011-12-22 US US13/996,733 patent/US9505826B2/en active Active
- 2011-12-22 MX MX2013007392A patent/MX2013007392A/es unknown
- 2011-12-22 EA EA201390923A patent/EA201390923A1/ru unknown
- 2011-12-22 WO PCT/AU2011/001662 patent/WO2012083370A1/en not_active Ceased
- 2011-12-22 EP EP11850362.2A patent/EP2654790B1/en active Active
- 2011-12-22 JP JP2013544971A patent/JP6147670B2/ja active Active
- 2011-12-22 BR BR112013016235-0A patent/BR112013016235B1/pt active IP Right Grant
- 2011-12-22 PT PT11850362T patent/PT2654790T/pt unknown
- 2011-12-22 KR KR1020137019148A patent/KR101941514B1/ko active Active
-
2013
- 2013-06-20 IL IL227081A patent/IL227081B/en active IP Right Grant
- 2013-07-08 ZA ZA2013/05123A patent/ZA201305123B/en unknown
-
2016
- 2016-12-28 JP JP2016255652A patent/JP6334669B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503209A5 (enExample) | ||
| KR102083230B1 (ko) | Il-17a, il-17f 및/또는 il-17a/f를 겨냥하는 아미노산 서열 및 이를 포함하는 폴리펩타이드 | |
| KR101676269B1 (ko) | 인터루킨-13 결합 단백질 | |
| JP7274417B2 (ja) | ４－１ｂｂ結合タンパク質及びその使用 | |
| JP7161400B2 (ja) | Ｃｄ２２に結合する抗体分子 | |
| CN101983207B (zh) | 抗mif抗体 | |
| JP2012530496A5 (enExample) | ||
| MX2012005086A (es) | Antagonistas de il-17a. | |
| AU2016293118A1 (en) | Antibody molecules which bind CD45 | |
| TW202019969A (zh) | Ｓｔ２ｌ拮抗劑及使用方法 | |
| JP2013529059A5 (enExample) | ||
| WO2015137843A1 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| AU2016293119A1 (en) | Antibody molecules which bind CD79 | |
| TW201107345A (en) | Immunoglobulins | |
| US20230087378A1 (en) | Multi-specific antibody with binding specificity for human il-13 and il-17 | |
| IL293813A (en) | Multi-specific antibodies | |
| JP7082053B2 (ja) | ＴＮＦαに結合する抗体分子 | |
| TW202415677A (zh) | 抗TNFα抗體及組合物 | |
| JP7710446B2 (ja) | ヒトｉｌ‐１３に結合特異性を有する抗体 | |
| US20230374148A1 (en) | Binding molecules that multimerise cd45 | |
| CN115551538A (zh) | 干扰IL-1β受体信号转导的药剂 | |
| HK40069078A (en) | Multi-specific antibody with binding specificity for human il-13 and il-17 | |
| JPWO2021249990A5 (enExample) | ||
| HK40069079A (en) | Antibody with binding specificity for human il-13. | |
| EA048161B1 (ru) | Антитела, специфичные для tl1a, и их применение |